Alto Neuroscience, Inc. financial data

Symbol
ANRO on NYSE
Location
Mountain View, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1807% % 0.65%
Debt-to-equity 25% % 47%
Return On Equity -47% % 3.9%
Return On Assets -38% % -14%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 31,066,335 shares 15%
Common Stock, Shares, Outstanding 27,168,369 shares 0.74%
Entity Public Float $266,500,000 USD
Weighted Average Number of Shares Outstanding, Basic 27,104,000 shares 0.54%
Weighted Average Number of Shares Outstanding, Diluted 27,104,000 shares 0.54%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $44,423,000 USD -3.1%
General and Administrative Expense $21,883,000 USD 25%
Operating Income (Loss) $66,306,000 USD -4.6%
Nonoperating Income (Expense) $4,049,000 USD -32%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $62,257,000 USD -8.4%
Earnings Per Share, Basic -2 USD/shares 55%
Earnings Per Share, Diluted -2 USD/shares 55%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $137,816,000 USD -24%
Other Assets, Current $23,000 USD -85%
Assets, Current $139,448,000 USD -24%
Property, Plant and Equipment, Net $2,029,000 USD -14%
Operating Lease, Right-of-Use Asset $4,459,000 USD -15%
Assets $147,006,000 USD -23%
Accounts Payable, Current $2,059,000 USD -8.6%
Employee-related Liabilities, Current $3,210,000 USD -17%
Accrued Liabilities, Current $6,986,000 USD -15%
Liabilities, Current $9,045,000 USD -35%
Operating Lease, Liability, Noncurrent $3,966,000 USD -14%
Liabilities $35,449,000 USD 33%
Accumulated Other Comprehensive Income (Loss), Net of Tax $14,000 USD
Retained Earnings (Accumulated Deficit) $185,452,000 USD -51%
Stockholders' Equity Attributable to Parent $111,557,000 USD -32%
Liabilities and Equity $147,006,000 USD -23%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $16,556,000 USD -51%
Net Cash Provided by (Used in) Financing Activities $9,127,000 USD -93%
Net Cash Provided by (Used in) Investing Activities $24,000 USD 89%
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 27,168,369 shares 0.74%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $7,475,000 USD -106%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $138,316,000 USD -24%
Interest Paid, Excluding Capitalized Interest, Operating Activities $311,000 USD 25%
Deferred Tax Assets, Valuation Allowance $37,400,000 USD 62%
Deferred Tax Assets, Gross $39,365,000 USD 70%
Operating Lease, Liability $5,386,000 USD 4209%
Depreciation $200,000 USD 0%
Payments to Acquire Property, Plant, and Equipment $24,000 USD -89%
Lessee, Operating Lease, Liability, to be Paid $7,066,000 USD
Operating Lease, Liability, Current $1,118,000 USD 56%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,216,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $917,000 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 112%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,680,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,456,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $12,124,000 USD 15%
Preferred Stock, Shares Issued 0 shares
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,500,000 USD
Operating Lease, Payments $0 USD
Additional Paid in Capital $296,992,000 USD 3%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $576,000 USD 50%
Deferred Tax Assets, Net of Valuation Allowance $1,965,000 USD 1246%
Share-based Payment Arrangement, Expense $7,728,000 USD 16%